Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes

Brain Pathology

Volumn 8, Issue 4, 1998, Pages 655-667

  Newcomb, Elizabeth W ^a,c   Cohen, Henry ^a,c   Lee, Suzanne R ^a   Bhalla, Sandhya K ^a   Bloom, Joanna ^a   Hayes, Roberta L ^b   Miller, Douglas C ^a,c  

^a NEW YORK UNIVERSITY   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0031679407     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1998.tb00191.x     Document Type: Article

References (61)

1. Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625
2. Salminen E, Nuutinen JM, Huhtala S (1996) Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A: 1918-1923
3. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69: 236-240
4. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WKA (1996) Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56: 694-699
5. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643
6. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang H-JS (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-508
7. Hall PA, Meek D, Lane DP (1996) p53-integrating the complexity. J Pathol 180: 1-5
8. Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astroeytic tumors. J Neurosurg 81:427-436
9. Bogler O, Huang HJ, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Glia 15: 308-327
10. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kielhues P (1995) Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Vlrchows Arch 427: 113-118
11. von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15: 328-338
12. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7: 871-875
13. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC (1997) bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol 94: 369-375
14. Scherer HJ (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40: 159-198
15. Dropcho EJ, Soong S-J (1996) The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology 47: 684-690
16. Kleihues P, Burger PC, Plate KH, Ohgaki H, Cavenee WK (1997) Glioblastoma. In Pathology and Genetics of Tumours of the Nervous System. Kleihues P, Cavenee WK (eds.), IARC Press, Lyon, pp 16-24
17. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26
18. van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG (1994) p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 86: 1011-1017
19. Chozick BS, Weicker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW (1994) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73: 406-415
20. Reifenberger J, Ring GU, Gies U, Cobbers JMJL, Oberstrab J, An H-X, Niederacher D, Wechsler W, Reifenberger G (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 7: 822-831
21. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1997) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224
22. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H (1997) Amplification and Overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185
23. Louis DN (1997) A molecular genetic model of astrocytoma histopathology. Brain Pathol 7: 755-764
24. James CD, Carlbom E, Dumanskt JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK (1988) Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551
25. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestler OD, Seizinger BR (1992) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77: 295-301
26. Barker FG, Davis RL, Chang SM, Prados MD (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77: 1161-1166
27. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson ADJ. (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66: 373-385
28. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, Kimmel DW. (1994) Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic. and molecular markers. Cancer 74: 920-927
29. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumcke I, von Deimling A, Schlegel U (1996) Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-α pathway in human astrocytic gliomas. J Neurosurg 85: 634-641
30. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86: 121-130
31. Baxendine-Jones J, Campbell i, Ellison D (1997) p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clinical Neuropathol 16: 332-336
32. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E (1997) MDM2 and p53 expression in gliomas. a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75: 1269-1278
33. Rainov NG, Dobberstein K-U, Bahn H, Holzhausen H-J, Lauten-schlager C, Heidecke V, Burkert W (1997) Prognostic factors in malignant glioma influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28
34. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clinical Cancer Res 3: 523-530
35. Kleihues P, Burger PC, Scheithauer BW (1993) Histological Typing of Tumors of the Central Nervous System. Springer-Verlag Berlin, Heidelberg, New York
36. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb, EW (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9: 949-954
37. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235
38. INK4 genes in astrocytomas Diag Mol Pathol 6: 15-122.
39. Soong R, Iacopetta BJ (1997) A rapid and nonisotopic method for screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 10: 252-258
40. Lee, ET (1980) Statistical Methods for Survival Data Analysis, Lifetime Learning Publication, Belmont, CA
41. Siegel S, Castellan, Jr., NJ (1988) Nonparametric Statistics for the Behavioral Sciences. McGraw Hill, New York, New York
42. Zar JH (1984) Biostatistical Analysis, Prentice-Hall, Inc., Engelwood Cliffs, NJ
43. Maxwell S and Delaney H. (1990). Designing Experiments and Analyzing Data, Wadsworth Publishing Co., Belmont, CA
44. Louis DN, von Deimling A, Chung RY, Rubio M-P, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38
45. Rubio M-P, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN (1993) Accumulation of wild-type p53 protein in human astrocytomas. Cancer Res 53: 3465-3467
46. Koga J, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J (1994) Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87: 225-232
47. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DO, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330
48. Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW (1995) Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001
49. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739
50. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H (1997) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas Acta Neuropathol 94: 303-309
51. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J (1992) Amplification of epidermal-growth-factor-receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51: 84-90
52. Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B, Bigner DD (1988) Gene amplification in malignant human gliomas: clinical and histopathological aspects. J Neuropathol Exp Neurol 47: 191-203
53. Schlegel J, Merdes A. Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M (1994) Amplification of the epidermal-growth-factor-receptor-gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77
54. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS, James CD (1994) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807
55. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153
56. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN (1998) Molecular genetic correlates of pl6, cdk4, and pRb immunohistochemistry in gljoblastomas. J Neuropathol Exp Neurol 57: 122-130
57. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
58. A, interacts with MDM2 and neutralizes MDM2′s inhibition of p53. Cell 92: 713-723
59. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734
60. Wu X, Bayle H, Olson D, Levine AJ (1993) The p53-mdm-2 autoregulatory feedback loop. Genes & Develop 7: 1126-1132
61. Matsumoto R, Tada M, Nozaki M, Zhang C-L, Sawamura Y, Abe H (1998) Short alternative splice transcripts of the mom2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 58: 609-613